Search research articles
Contact Us
Filters
Showing results (11-20 of 184) with videos related to
Page
of 19
Sort By:
Expert Review of Anticancer Therapy
|
August 23, 2005
Docetaxel in the treatment of breast cancer: current experience and future prospects
Jean-Marc Nabholtz, Joseph Gligorov
Women'S Health (London, England)
|
October 7, 2009
Taxane therapy for early stage breast cancer
Jean-Marc Nabholtz, Joseph Gligorov
Expert Opinion on Pharmacotherapy
|
June 17, 2005
The role of taxanes in the treatment of breast cancer
Jean-Marc Nabholtz, Joseph Gligorov
Drug Safety
|
September 2, 2006
Cardiovascular safety profiles of aromatase inhibitors : a comparative review
Jean-Marc Nabholtz, Joseph Gligorov
Current Opinion in Oncology
|
October 7, 2017
New anti-HER2 agents: from second-generation tyrosine kinases inhibitors to bifunctional antibodies
Joseph Gligorov, Sandrine Richard, Vladimir Todorovic
Nature Reviews. Clinical Oncology
|
October 17, 2022
Systemic therapy for early-stage breast cancer: learning from the past to build the future
Elisa Agostinetto, Joseph Gligorov, Martine Piccart
Breast (Edinburgh, Scotland)
|
December 7, 2007
Adjuvant and extended adjuvant use of aromatase inhibitors: reducing the risk of recurrence and distant metastasis
Joseph Gligorov, Kathleen Pritchard, Paul Goss
Chinese Clinical Oncology
|
January 9, 2018
Emilia: use cunning to survive cancer
Joseph Gligorov, Sandrine Richard, Xavier Pivot
European Journal of Breast Health
|
July 14, 2020
Breast Cancer Management during the COVID 19 Pandemic: French Guidelines
Emile Daraï, Carole Mathelin, Joseph Gligorov
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 13, 2011
Castration-dependent pharmacokinetics of docetaxel: do sex and/or ABCB1 polymorphism also matter?
Joseph Gligorov, Anne Fajac, Jean-François Bernaudin
Page
of 19
Search research articles
Search
Showing results (11-20 of 184) with videos related to
Sort By:
Page
of 19
Expert Review of Anticancer Therapy
|
August 23, 2005
Docetaxel in the treatment of breast cancer: current experience and future prospects
Jean-Marc Nabholtz, Joseph Gligorov
Women'S Health (London, England)
|
October 7, 2009
Taxane therapy for early stage breast cancer
Jean-Marc Nabholtz, Joseph Gligorov
Expert Opinion on Pharmacotherapy
|
June 17, 2005
The role of taxanes in the treatment of breast cancer
Jean-Marc Nabholtz, Joseph Gligorov
Drug Safety
|
September 2, 2006
Cardiovascular safety profiles of aromatase inhibitors : a comparative review
Jean-Marc Nabholtz, Joseph Gligorov
Current Opinion in Oncology
|
October 7, 2017
New anti-HER2 agents: from second-generation tyrosine kinases inhibitors to bifunctional antibodies
Joseph Gligorov, Sandrine Richard, Vladimir Todorovic
Nature Reviews. Clinical Oncology
|
October 17, 2022
Systemic therapy for early-stage breast cancer: learning from the past to build the future
Elisa Agostinetto, Joseph Gligorov, Martine Piccart
Breast (Edinburgh, Scotland)
|
December 7, 2007
Adjuvant and extended adjuvant use of aromatase inhibitors: reducing the risk of recurrence and distant metastasis
Joseph Gligorov, Kathleen Pritchard, Paul Goss
Chinese Clinical Oncology
|
January 9, 2018
Emilia: use cunning to survive cancer
Joseph Gligorov, Sandrine Richard, Xavier Pivot
European Journal of Breast Health
|
July 14, 2020
Breast Cancer Management during the COVID 19 Pandemic: French Guidelines
Emile Daraï, Carole Mathelin, Joseph Gligorov
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 13, 2011
Castration-dependent pharmacokinetics of docetaxel: do sex and/or ABCB1 polymorphism also matter?
Joseph Gligorov, Anne Fajac, Jean-François Bernaudin
Page
of 19